1 Maemondo M, Minegishi Y, Inoue A, Kobayashi K, Harada M, Okinaga S, Morikawa N, Oizumi S, Tanaka T, Isobe H, Kudoh S, Hagiwara K, Nukiwa T, and Gemma A. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. J Thorac Oncol. 2012 Sep;7(9):1417-22.
2 Inoue A, Kobayashi K, Usui K, Maemondo M, Okinaga S, Mikami I, Ando M, Yamazaki K, Saijo Y, Gemma A, Miyazawa H, Tanaka T, Ikebuchi K, Nukiwa T, Morita S, Hagiwara K; North East Japan Gefitinib Study Group. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol. 2009 Mar 20;27(9):1394-400. doi: 10.1200/JCO.2008.18.7658. Epub 2009 Feb 17.
3 Eiki Ichihara, Katsuyuki Hotta, Nagio Takigawa, Kenichiro Kudo, Yuka Kato,
Yoshihiro Honda, Hiromi Hayakawa, Daisuke Minami, Akiko Sato, Masahiro Tabata, Mitsune Tanimoto, Katsuyuki Kiura: Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations. Lung Cancer 81 (2013) 435– 439
4 Igawa S. · Sasaki J. · Otani S. · Ishihara M. · Takakura A. · Katagiri M. · Masuda N.: Impact of Smoking History on the Efficacy of Gefitinib in Patients with Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutations. Oncology 2015; 89:275-280
5 KUNIHIKO MIYAZAKI, SHINYA SATO, TAKAHIDE KODAMA, TOMOHIRO TAMURA, KATSUNORI KAGOHASHI, HIROAKI SATOH and NOBUYUKI HIZAWA, Effect of acid suppressants on the efficacy of tyrosine kinase
inhibitors in patients with epidermal growth factor receptor‑mutated non‑small‑cell lung cancer. MOLECULAR AND CLINICAL ONCOLOGY 4: 873-877, 2016
6 Shigehiro Yagishita and Akinobu Hamada. Clinical Pharmacology of EGFR/Met Inhibitors in Non-Small Cell Lung Cancer. Current Drug Targets, 2014, 15, 1263-1272
7 Samir D. Undevia, Gonzalo Gomez-Abuin and Mark J. Ratain. Pharmacokinetic Variability Of Anticancer Agents: Nature, VOLUME 5, JUNE 2005, 457-458
8 Shuang Xin, Yuanyuan Zhao, Xueding Wang, Yan Huang, Jing Zhang, Ying Guo, Jiali Li, Hongliang Li, Yuxiang Ma, Lingyan Chen, Zhihuang Hu, Min Huang, and Li Zhangb. The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations. Scientific Reports | 5:12675 | DOI: 10.1038/srep12675
9 Yuan-Yuan Zhao, Su Li, Yang Zhang, Hong-Yun Zhao, Hai Liao, Ying Guo, Yan-Xia Shi , Wei Jiang, Cong Xue, Li Zhang: The relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinib. Med Oncol (2011) 28:697–702
10 European Medicines Agency. Iressa (gefitinib) Assessment Report, July 2009. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001016/WC500036361.pdf. Feb 20, 2014
11 Jie S, John S.M, Di B, Guohua A. Enzyme-and transporter- Mediated Drug Interactions with Small Molecule Tyrosine Kinase Inhibitors. Journal of pharmaceutical sciences 103: 3810-3833, 2014
12 Can Zhao, Shu-Yan Han and Ping-Ping Li. Pharmacokinetics of Gefitinib: Roles of Drug Metabolizing Enzymes and Transporters. Current Drug Delivery, 2017, 14, 282-288
13 McKillop, AD McCormick, A Millar, GS Miles, PJ Phillips and M Hutchison: Cytochrome P450-dependent metabolism of gefitinib. Xenobiotica, Jan 2005, 35(1): 39-50
14 McKillop, AD McCormick, A Millar, GS Miles, PJ Phillips, KJ Pickup, N Bushby and M Hutchison: In vitro metabolism of gefitinib in human liver microsomes. Xenobiotica, Nov/ Dec 2004, vol 34, No 11/12, 983-1000
15 R.M. Franke, E.R. Gardner and Sparreboom: Pharmacogenetics of Drug Transporters. Current Pharmaceutical Design, 2010, 16, 220-230
16 Li J, Cusatis G, Brahmer J, Sparreboom A, Robey RW, Bates SE, Hidalgo M, Baker SD: Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther. 2007 Mar;6(3):432-8. Epub 2007 Mar 29.
17 Wei Mo, Jian-Ting Zhang: Human ABCG2: structure, function, and its role in multidrug resistance. Int J Biochem Mol Biol 2012;3(1):1-27
18 Maricla Galetti, Pier Giorgio Petronini, Claudia Fumarola, Daniele Cretella, Silvia La Monica, Mara Bonelli, Andrea Cavazzoni, Francesca Saccani, Cristina Caffarra, Roberta Andreoli , Antonio Mutti, Marcello Tiseo, Andrea Ardizzoni, Roberta R. Alfieri: Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines. PLOS ONE | DOI:10.1371/journal.pone.0141795 November 4, 2015
19 Caroline A. Lee, Meeghan A. O’Connor, Tasha K. Ritchie, Aleksandra Galetin, Jack A. Cook, Isabelle Ragueneau-Majlessi, Harma Ellens, Bo Feng, Mitchell E. Taub, Mary F. Paine, Joseph W. Polli, Joseph A. Ware, and Maciej J. Zamek-Gliszczynski: Breast Cancer Resistance Protein (ABCG2) in Clinical Pharmacokinetics and Drug Interactions: Practical Recommendations for Clinical Victim and Perpetrator Drug-Drug Interaction Study Design. Drug Metab Dispos. 2015 Apr;43(4):490-509. doi: 10.1124/dmd.114.062174. Epub 2015 Jan 13.
20 Kunihiro Suzuki, Kosuke Doki, Masato Homma, Hirofumi Tamaki, Satoko Hori, Hisakazu Ohtani, Yasufumi Sawada & Yukinao Kohda: Co-administration of proton
pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol / 67:1 / 44–49
21 Daisuke Kobayashi, Ichiro Ieiri, Takeshi Hirota, Hiroshi Takane, Shinji Maegawa, Junzo Kigawa, Hiroshi Suzuki, Eiji Nanba, Mitsuo Oshimura, Naoki Terakawa, Kenji Otsubo, Kazunori Mine and Yuichi Sugiyama: Functional Assessment Of ABCG2 (BCRP) Gene Polymorphisms To Protein Expression In Human Placenta. DRUG METABOLISM AND DISPOSITION Vol. 33, No. 1, 33:94–101, 2005
22 Imai Y, Nakane M, Kage K, Tsukahara S, Ishikawa E, Tsuruo T, Miki Y, Sugimoto Y. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther. 2002; 1(8):611–616.
23 Maeda K, Sugiyama Y. Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. Drug Metab Pharmacokinet. 2008; 23(4):223–235. doi: 10.2133/dmpk.23.223.
24 Mizuarai S, Aozasa N, Kotani H. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int J Cancer. 2004; 109(2):238–246. doi: 10.1002/ijc.11669.
25 Kobayashi D, Ieiri I, Hirota T, Takane H, Maegawa S, Kigawa J, Suzuki H, Nanba E, Oshimura M, Terakawa N, Otsubo K, Mine K, Sugiyama Y. Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos. 2005; 33:94–101.
26 Oscar Juan and Sanjay Popat: Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications. Ther Adv Med Oncol 2017, Vol. 9(3) 201–216
27 Yuji Okuda, Kazuhiro Sato, Kazuhisa Sudo, Yukiyasu Hasegawa, Mariko Asano, Hajime Miura, Masahide Takeda, Masaaki Sano, Hiroyuki Watanabe, Hiroyuki Kobayashi, Takenori Niioka, Masatomo Miura, Hiroshi Ito. Low plasma concentration of gefitinib in patients with EGFR exon 21 L858R point mutations shortens progression-free survival. Cancer Chemother Pharmacol (2017) 79:1013–1020
28 Hayato Yokota, Kazuhiro Sato, Yuji Okuda, Hiroyuki Kobayashi, Masahide Takeda, Mariko Asano, Hiroshi Ito, Masatomo Miura: Effects of Histamine 2-receptor Antagonists and Proton Pump Inhibitors on the Pharmacokinetics of Gefitinib in Patients With Nonesmall-cell Lung Cancer. Clin Lung Cancer. 2017 Nov; 18 (6): e433-e439.
29 Jiri Horak, Jeff White, Adrian L. Harris, Mark Verrill, James Carmichael, Alison Holt, Mireille Cantarini, Merran Macpherson, Alan Swaisland, Helen Swaisland, Chris Twelves: The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib. Cancer Chemother Pharmacol (2011) 68:1485–1495
30 Swaisland HC1, Cantarini MV, Fuhr R, Holt A. , Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics. Clin Pharmacokinet. 2006;45(6):633-44.
31 Cohen MH, Williams, G.A et al. United States food and drug administration drug approval summary: Gefitinib tablets. Clin Cancer Res, 2004, 10(4), 1212-1218
32 Gardner ER, Figg WD, Sarreboom A: Pharmacogenenomics of the Human ATP-Bindng Castle Transporrter ABCG2. Current Pharmacogenomics 2006; 4(4): 331-44
33 Cusatis G, Sparreboom A: Pharmacogenomic importance of ABCG2. Pharmacogenomics 2008, 9(8):1005-9.
34 Xueqin Chen, Dadong Chen, Shaoyu Yang, Ruobing Ma, Yuelong Pan, Xin Li and Shenglin Ma: Impact of ABCG2 polymorphisms on the clinical outcome of TKIs therapy in Chinese advanced non-small-cell lung cancer patients. Cancer Cell International (2015) 15:43
35 Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll RG, Verweij J, Ludovini V, Villa E, Hidalgo M, Sparreboom A, Baker SD: Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst. 2006 Dec 6; 98(23):1739-42.
36 Lina Tang, Chunling Zhang, Hairong He, Zhenyu Pan, Di Fan, Yinli He, Haisheng You, and Yuanjie Li: Associations between ABCG2 gene polymorphisms and gefitinib toxicity in non-small cell lung cancer: a meta-analysis. Onco Targets Ther. 2018; 11: 665–675.
37 Ma Y, Xin S, Huang M, et al. Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters. Pharmacogenomics J. 2016; 17(4):325–330
38 Hiroyuki Kobayashi, Kazuhiro Sato, Takenori Niioka, Masahide Takeda, Yuji Okuda, Mariko Asano, Hiroshi Ito, Masatomo Miura: Effects of polymorphisms in CYP2D6 and ABC transporters and side effects induced by gefitinib on the pharmacokinetics of the gefitinib metabolite, O-desmethyl gefitinib. Med Oncol (2016) 33:57